↑  Read the latest from the desks  ·  fresh intelligence, published daily✦Quiet reading✦No ads, ever

✦Corporate brand & media services✦Made in Virginia Beach since 1997✦

Aligos Therapeutics: Old boat (three warning signs)Old boat

Aligos Therapeutics $ALGS

Saw revenue fall 39.5% in FY2025 to $2 million, operating margin -4025% against a -15.8% median for biological products, (no diagnostic substances), equity 60.5% of assets.

Last filing8-K · Item 1.01 Entry into a Material Definitive Agreement, 15 Sept 2026

Health watchDirector or officer change ×2 · 26 Jun 2026
Follow its filings →
Next year, 80%$1M–$2M
Growth, on the year−39.5%
Operating margin−4024.9%
Equity of assets60.5%
Edgarette’s full reading · exposure, experience, soundness, credibility, range

🫧 Edgar looked up Aligos Therapeutics, Inc. ($ALGS). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-09-15. 9 event filings (8-K) in the past twelve months.

🔖 Exposure: revenue $2.2M (FY2025). Experience: revenue down 39.5% on the year; operating margin -4024.9%, down from -2469.0%. Soundness: equity 60.5% of assets, return on equity -45.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $971K and $1.7M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -4024.9% against a -15.8% median; growth -39.5% against 21.4%.

Read from its own SEC filings · nothing written, nothing inferred

Aligos Therapeutics, Inc. against its own record and its peers
Operating marginPeer median -15.8%-4024.9%Revenue, on the yearPeer median 21.4%-39.5%Equity of assetsPeer median 58.6%60.5%Return on equityPeer median -6.5%-45.2%Gold tick: the median of 25–31 peers with $50M+ revenue in biological products, (no diagnostic substances)

Speed and cash · fiscal 2025

Cash Compass🌊 In between · no clear cash pattern yet
Inside viewTurns -200.0% of revenue into operating cash; revenue shrinking 39.5% a year over three years; no common dividend.
Outside viewAmong under $50M companies: 14th percentile for cash, 8th for growth. cash growth

Both views must agree for a label · a description, not advice.

Cash flow (op · inv · fin · free)−$83M · −$38M · $102M · —
Investment book (cash · short · long)$18M · $60M · — · current ratio 3.90
Revenue swing · equity of assets2.6% · 60.5%

Aligos Therapeutics is growing slower than its size class, with steadier revenue. Its own audited SEC figures.

The figures, as filed

Fiscal year end2025-12-31
Revenue$2M
Revenue, on the year−39.5%
Revenue, a year over the record—
Operating margin−4024.9%
Operating margin, prior year−2469.0%
Net margin−1106.7%
Research and development$69M · 3177.2% of revenue
Total debt—
Equity of assets60.5%
Return on equity−45.2%
Payout of profit—
Dividend per share—
Earnings per share$-2.45
Book value per share$5.42
Revenue per share$0.22
Shares outstanding9,884,955
Audited years read5

Peers: the median of 31 filers with $50M+ revenue in biological products, (no diagnostic substances).

Classic signals · fiscal 2025Altman Z″ -24.15 distress zone 1968Piotroski F 3 of 9 middling 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals 73.5% earnings ahead of cash 1996DuPont ROE -196.9% = margin -1106.7% × turns 0.03 × leverage 6.46

What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →

Health HarborAligos Therapeutics sails as: Old boat

Health watch · 12 monthsDirector or officer change ×2

Sailing speed follows growth: -39.5% a year crosses the harbor in 120 seconds.

🌊 Visit the Bay →
  • operating cash flow was negative
  • operating loss: a margin of -4024.9% in FY2025
  • revenue is hard to predict: its 80% range is ±28%

Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.

Recent filings

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company

1 · Follow

Follow their filings

Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.

On Bluesky: follow Edgar & Edgarette.

2 · Price it

A new leader’s rebrand and launch

Priced live by the same engine as our estimator, from the catalogue at wholesale.

Price the printing · Open the full estimator

✦ Build the kit yourself
3 · Confirm

Check it with Jenny

Most buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.

Jenny Huang Goodman MPA MSc MHSA, Principal

Book a time (757) 390-0424
Independence. Every range, flag and score on these boards is identical for everyone. Clients of POPS4 or Hako Shikin receive no different numbers, no earlier access and no say in what is published. The service lines shown beside each board describe work we do; they never change the data. For reviewers: Method · Terms of use · Status
Free · unsponsored · source-linked

Clean data. No ads. Not now, not later.

Nine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.

Every row is a filing.Straight from the company's own SEC document, linked. Nothing written, nothing inferred.
Nobody is watching you read.No ad trackers, no cookies from us. Our page counts are cookieless.
One email, one job.Watch a company and we hold that address for the alert alone. One tap ends it. Never shared, never passed on.
The house pays for this.Corporate event programs, corporate supplies and branded merchandise, since 1997. That is what funds the desks, under the house's own vendor standards.
Free to reuse with credit · CC BY 4.0 · how the boards are built
Data & Disclosure Notice: Edgar and Edgarette are automated software. Every figure on this page is calculated by software from public filings made by companies and funds with the U.S. Securities and Exchange Commission (EDGAR) and is published without individual human review. The accuracy and completeness of those filings are the responsibility of the filers; reports can contain errors and can be amended. Figures are shown as filed and as of each filing's date, and this page may be corrected or updated without notice. Ranges, expected returns, rankings, boats and other measures are statistical descriptions of past filings, not ratings, price forecasts, company guidance or recommendations; past results do not guarantee future results. This is general information published for all readers, not advice tailored to any person's portfolio, needs or circumstances, and nothing here is financial, investment, actuarial, legal, tax or other professional advice. Actuaries and other professionals who use these figures remain responsible for reviewing them for reasonableness and consistency against the original filings and for disclosing their reliance on them. No company, fund or reinsurer pays to be included or ranked. Provided as is, without warranty of any kind. Not affiliated with or endorsed by the SEC or by any company, fund or reinsurer named. All trademarks remain the property of their owners.